zw251
·Code: ZW251
zw251: developed by 1 company · 1 clinical trial tracked.
zw251 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect zw251 to ZYME; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could zw251 → ZYME affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Zymeworks Inc. (ZYME) | Phase 1 |
Clinical Trials (1)
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma
Primary endpoint: Incidence of dose-limiting toxicities (DLTs; Part 1)
Interventionalopen100 targetStarted 2025-10Completion 2028-0525 sites · Ireland, Japan, Portugal, Spain…Zymeworks BC Inc.
Frequently asked questions
Who is developing zw251?
zw251 is being developed by Zymeworks Inc..
How many clinical trials involve zw251?
BioSniper tracks 1 clinical trial involving zw251.